CAJ | 학술논문

目的:探讨米力农治疗高龄肺心病心力衰竭(HF)的安全性和临床疗效.方法:选取在ICU住院的年龄≥80岁肺心病HF病人104例,随机分为对照组和治疗组两组,两组患者均给予基础治疗,对照组加用西地兰,治疗组加用米力农,观察7天,比较两组患者的HF治疗效果、血浆氨基末端B型利钠肽前体(NT-proBNP)、血气分析变化及心律失常情况.结果:治疗组有效率(90.4%)明显高于对照组(57.7%),有显著差异(P<0,01);治疗组用药后NT-proBNP下降程度与对照组比较差异有统计学意义(P<0.05);治疗组与对照组治疗后室性心律失常发生率、死亡率无明显差异(P>0.05);两组患者治疗前后自身比较发现PaO2升高、PaCO2降低、pH改善,但两组间治疗后比较PaO2、PaCO2无显著差异(P>0.05),pH变化有极显著差异(P<0.01).结论:米力农短期(≤7天)、小剂量使用治疗高龄肺心病HF是安全、有效的.
목적:탐토미력농치료고령폐심병심력쇠갈(HF)적안전성화림상료효.방법:선취재ICU주원적년령≥80세폐심병HF병인104례,수궤분위대조조화치료조량조,량조환자균급여기출치료,대조조가용서지란,치료조가용미력농,관찰7천,비교량조환자적HF치료효과、혈장안기말단B형리납태전체(NT-proBNP)、혈기분석변화급심률실상정황.결과:치료조유효솔(90.4%)명현고우대조조(57.7%),유현저차이(P<0,01);치료조용약후NT-proBNP하강정도여대조조비교차이유통계학의의(P<0.05);치료조여대조조치료후실성심률실상발생솔、사망솔무명현차이(P>0.05);량조환자치료전후자신비교발현PaO2승고、PaCO2강저、pH개선,단량조간치료후비교PaO2、PaCO2무현저차이(P>0.05),pH변화유겁현저차이(P<0.01).결론:미력농단기(≤7천)、소제량사용치료고령폐심병HF시안전、유효적.
@@@@Objective:To explore milrinone in the treatment of the elderly pulmonary heart disease heart failure (HF) safety and clinical efficacy. Methods:Selected in the ICU stay ≥80 years of age in patients with pulmonary heart HF 104 cases were randomly divided into two groups of control and treatment groups, the two groups of patients were given basic treatment and control group plus the Cedilanid, the treatment group milrinoneobserved for seven days, the the HF therapeutic effect of the two groups were compared, the precursor of plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP), blood gas analysis, change and arrhythmia situation. Results:Efficient treatment group(90.4%) was significantly higher (57.7%), with significant differences(P<0,01);treatment group after treatment NT-proBNP decreased degree of control group difference was statistically significant (P<0.05);treatment group and the control group after treatment of ventricular arrhythmias incidence, mortality was no significant difference(P>0.05);own comparison found two groups of patients before and after treatment PaO2 increased, PaCO2 decreased, pH improvement, but the twobetween the two groups after treatment PaO2, PaCO2 was no significant difference(P>0.05), pH changes very significant difference(P<0.01). Conclusions:Milrinone short-term (≤7 days), low-dose use is safe and effective treatment of elderly pulmonary heart HF.